

# Development of a PBM Index for Evaluation of Performances of PBM

OSSTEM IMPLANT HEADQUARTERS  
AUDITORIUM  
MAGOK, SEOUL, KOREA  
23<sup>rd</sup> Oct 2025

Young-Woo Kim, MD, PhD, FRCS

Professor, Department of Cancer Control and Population Health,  
National Cancer Center Graduate School of Cancer Science & Policy  
Staff Surgeon, Center for Gastric Cancer, National Cancer Center.



# Patient Blood Management

**1st Pillar**

**Optimise  
red cell  
mass**

**2nd Pillar**

**Minimise  
Blood loss  
& bleeding**

**3rd Pillar**

**Harness &  
optimise  
physio-  
logical  
reserve of  
anaemia**

**Multidisciplinary team approach**

*Hofmann A, Farmer S, Shander A. [Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management.](#) Oncologist. 2011;16 Suppl 3:3-11*

# A Literature Review of Patient Blood Management (PBM) Outcomes

- **5 Meta-analyses, 5 Randomized Controlled Trials (RCTs), and 5 Systematic Reviews were included.**
- **Interventions:** PBM multimodal strategies such as pre-operative anemia management, active blood loss minimization (e.g., TXA), and restrictive transfusion thresholds.

# A Summary of Patient Blood Management Outcomes

Outcomes	Main Results
<b>RBC Transfusion Rate</b>	Confirmed PBM programs significantly reduce allogeneic RBC transfusion rates (e.g., by 39% or RR 0.60).
<b>Mortality</b>	Demonstrated PBM is associated with reduced overall mortality (e.g., RR 0.89), though some complexity was noted (not all studies show significance).
<b>Morbidity (complications)</b>	Confirmed PBM is associated with a reduced total number of complications and that TXA reduces bleeding without increasing the risk of thromboembolic events.
<b>Hospital length of stay (LoS) as cost-effective</b>	Established PBM is associated with reduced hospital length of stay (LoS) and is generally considered cost-effective.

# Randomized Controlled Trial (RCT)

Outcomes	Main Results
Avoiding allogeneic blood transfusions	Most frequent primary endpoint. Interventions like IV Iron or EPO were confirmed to be highly effective at avoiding allogeneic blood transfusions (e.g., up to 60% reduction in incidence).
Clinical Efficacy (Hb, Bleeding rate)	Proven successful treatment of the underlying issue: IV Iron leads to significantly higher Hemoglobin (Hb) recovery post-operatively; TXA significantly reduces direct bleeding rates.
Adverse events	Established the safety profile by showing no increase in adverse events (AEs) when comparing the intervention to the control.
Hospital length of stay	Proven to shorten the hospital length of stay and associated with better patient-reported outcomes (PROs).

# Systematic Review (SR)

Outcomes	Main Results/Conclusions
<b>Policy &amp; Consensus</b>	Affirmed that multimodal PBM programs are a critical patient safety initiative.
<b>Optimal Practice</b>	Established that restrictive transfusion practices (lower Hb thresholds) are the evidence-based standard in most patient populations.
<b>Intervention Feasibility</b>	Confirmed that core PBM components like IV iron are effective for anemia management and should be integrated into clinical pathways.
<b>Quality Assurance</b>	Highlighted gaps in current practice or methodology, such as confirming the accuracy of surgical blood loss measurement tools.

# Limitations in Measuring PBM Outcomes



**Heterogeneity of PBM  
Interventions and Patient  
Population**



**Challenges with Safety  
and Morbidity Outcomes**



**Difficulty in Measuring  
Appropriateness**



**Lagging Indicators for  
Program Success**



# The Unmet Need: Current Challenges in PBM Implementation and Evaluation


1. Lack of Standardized Evaluation Tool
2. Variability in Clinical Practice
3. Challenges with Safety and Morbidity Outcomes (rare, confounding factors)
4. Systemic Complexity and Financial Barriers

The development process relies on gathering expert consensus on core PBM indicators.





# Composite Index



**The Power of Aggregation: Translating Complexity into a Single Score**



To simplify complex, multidimensional realities into an easily understandable and actionable metric.

# Indices in Action: Examples from Other Fields

## Simplifying Decisions Across Finance, Health, and Development

<b>S&amp;P 500</b>	<b>Finance</b>	Aggregates the performance of 500 leading US public companies.
<b>Apgar Score</b>	<b>Pediatrics</b>	Aggregates 5 signs of newborn health (Appearance, Pulse, Grimace, Activity, Respiration) into a score (0-10) to assess immediate health.
<b>Human Development Index (HDI)</b>	<b>Socio-Economics</b>	Aggregates health (life expectancy), education (years of schooling), and standard of living (GNI per capita).

# Goal of The PBM Index

To aggregate 3 PBM Pillars across 3 Donabedian domains (S, P, O) into a single, standardized quality score.

Core Function	Why it Matters in Healthcare
Synthesis	Combines hundreds of individual patient data points (Hb, LoS, transfusion) into one comparable score.
Weighting	Allows experts to assign importance (weights) to critical components (e.g., Process is more critical than Structure).
Tracking	Provides a reproducible baseline and a clear target for measuring progress over time.

# Benefits of the PBM Index

From Guideline to Action



The PBM Index transforms the abstract concept of "good PBM" into a measurable, targetable score:

**Standardization**

**Objective  
Evaluation**

**Actionable  
Feedback**

# Structure of PBM Index

The PBM Index Structure: **Structure (S)**, **Process (P)**, **Outcome (O)** (Donabedian Model).

Domain	Weight (Proposed )	Focus	Impact
Structure (S)	20%	The resources and infrastructure in place	Essential foundation, but low weight reflects that protocols alone don't guarantee results.
Process (P)	40%	The actions taken by clinicians	High weight reflects that <b>doing the right thing</b> drives quality.
Outcome (O)	40%	The results for the patient	High weight reflects the ultimate goal of PBM: <b>better, safer patient care.</b>

# Delphi Survey Ongoing

Invitation to Participate in a Delphi Survey  
for PBM Index Indicator Development



Focus group 20

Korean expert 10

oversea exert 10

# Index Verification and Future Steps



**EVALUATION OF INDICATOR  
QUALITY**



**VERIFICATION OF THE  
WEIGHTING STRUCTURE**



**IDENTIFYING GAPS (FUTURE  
REFINEMENT)**





# PBM Index Validation Study

# Validation of PBM Index

---



The index aggregates multiple structural, process, and outcome metrics (3 Pillars) into a single score.



**Need for Proof:** We must prove that a high score truly correlates with superior clinical practice and improved patient outcomes





To rigorously validate the new PBM Index as an objective, reliable, and functional tool for quality improvement in Patient Blood Management.

# Observational Cohort & Construct Validation


Element	Description	Validation Mechanism
Study Cohort	multicenter hospitals selected to represent a range of PBM maturity (from non-implementing to highly mature).	Ensure the Index can differentiate between high and low performers .
Data Collection	Collect all necessary data for the Index calculation. <b>Hospitals operate as normal; no intervention is announced.</b>	The Index calculation must be reproducible and accurate.
Primary Validation Target	<b>Correlation of PBM Index Score vs. External Metrics</b>	A higher PBM Index Score must show a <b>significant correlation</b> with external metrics.
Expert Review	Present the Index scores and outcome data to the Delphi Expert Panel for qualitative confirmation.	Validate that the score meets <b>Criterion Validity</b> —experts agree high scores represent high-quality care.

Cluster Randomized Trial :  
PBM Index as the Primary Outcome



A large orange circle is positioned on the left side of the slide, partially cut off by the edge.

## Cluster Randomized Trial Protocol: PBM Index as the Primary Outcome

- Primary Objective  
To determine if the implementation of a structured, multimodal Patient Blood Management (PBM) Program in a healthcare facility leads to a significantly greater positive change in the composite PBM Index Score compared to facilities providing routine care.
- 
- A series of yellow dashed line segments are arranged in a curved, upward-pointing arc in the bottom right corner of the slide.

# Study Design

Element	Description
Design	<b>Multicenter, Parallel-group Cluster Randomized Trial (CRT)</b>
Clusters (Randomization Unit)	Hospitals or major surgical/anesthesia departments that are not currently operating a formal, comprehensive PBM program.
Randomization	Clusters are randomized 1:1 to either the Intervention Group (PBM Program Implementation) or the Control Group (Standard Care).
Duration	<b>Baseline Period (6 months):</b> Data is collected from all clusters to establish initial PBM Index scores. <b>Intervention Period (18 months):</b> Sufficient time for systemic change and clinical outcome realization.
Study Population	All adult patients undergoing moderate to major elective surgery at the participating hospitals, as this is the group most impacted by PBM initiatives.

# Intervention and Control

Arm	Name	The Intervention	Measurement
Intervention	PBM Program Group	Clusters receive funding, resources, training, and a mandate to establish a formal PBM program based on the <b>Three Pillars</b> (anemia management, blood loss minimization, physiological reserve optimization). Teams are directed to use the PBM Index and its S/P/O breakdown as their internal <b>QI score card</b> to guide efforts.	The PBM Index is calculated and provided <b>monthly</b> to drive iterative improvement.
Control	Standard Care Group	Clusters continue with their current clinical practice. They are not prohibited from transfusing appropriately but do <b>not</b> receive the structured PBM guidelines, PBM team support, or index-based feedback.	The PBM Index is calculated only at <b>Baseline</b> and at <b>18 months</b> (End-of-Study) to prevent contamination of the intervention.



# Primary and Secondary Outcomes

Outcomes	Measurement	Interpretation
<b>Primary Outcome</b>	<b>Absolute Increase in Composite PBM Index Score</b> (18-month score minus Baseline score).	<b>PBM Effectiveness:</b> Demonstrates that the PBM program significantly improved the overall quality and safety of patient blood management practice compared to standard care
<b>Secondary Outcome 1</b>	<b>TBD (e.g. Allogeneic RBC Transfusion Rate)</b>	<b>Clinical Benefit</b>
<b>Secondary Outcome 2</b>	<b>TBD (e.g. Post-operative Complication Rate and Hospital Length of Stay)</b>	<b>Patient Safety &amp; Efficiency</b>
<b>Secondary Outcome 3</b>	<b>TBD (e.g., Iron Treatment Rate)</b>	<b>Systemic Change</b>

Thank you for your attention!

---